Functionalizing electrospun fibers with biologically relevant macromolecules.
PDF (6.6M)
Journal: 2005/November - Biomacromolecules
ISSN: 1525-7797
Abstract:
The development of functionalized polymers that can elicit specific biological responses is of great interest in the biomedical community, as well as the development of methods to fabricate these biologically functionalized polymers. For example, the generation of fibrous matrices with biological properties and fiber diameters commensurate with those of the natural extracellular matrix (ECM) may permit the development of novel materials for use in wound healing or tissue engineering. The goal of this work is, therefore, to create a biologically active functionalized electrospun matrix to permit immobilization and long-term delivery of growth factors. In this work, poly(ethylene glycol) functionalized with low molecular weight heparin (PEG-LMWH) was fabricated into fibers for possible use in drug delivery, tissue engineering, or wound repair applications. Electrospinning was chosen to process the LMWH into fiber form due to the small fiber diameters and high degree of porosity that can be obtained relatively quickly and using small amounts of starting material. Both free LMWH and PEG-LMWH were investigated for their ability to be incorporated into electrospun fibers. Each of the samples were mixed with a carrier polymer consisting of either a 10 wt % poly(ethylene oxide) (PEO) or 45 wt % poly(lactide-co-glycolide) (PLGA). Field emission scanning electron microscopy (FESEM), energy-dispersive X-ray analysis (EDX), UV-vis spectroscopy, and multiphoton microscopy were used to characterize the electrospun matrices. The incorporation of heparin into the electrospun PEO and PLGA fibers did not affect the surface morphology or fiber diameters. The fibers produced had diameters ranging from approximately 100 to 400 nm. Toluidine blue assays of heparin suggest that it can be incorporated into an electrospun matrix at concentrations ranging from 3.5 to 85 mug per milligram of electrospun fibers. Multiphoton microscopy confirmed that incorporation of PEG-LMWH into the matrix permits retention of the heparin for at least 14 days. Improvements in the binding of basic fibroblast growth factor to the electrospun fibers were also observed for fibers functionalized with PEG-LMWH over those functionalized with LMWH alone. The combination of these results suggests the utility for producing electrospun fibers that are appropriately functionalized for use in biomaterials applications.
Open in
PUBMED | DOI | PMC | Google Scholar | Wikipedia
Relations:
Content
Citations
(25)
References
(26)
Drugs
(1)
Chemicals
(4)
Affiliates
(1)
Similar articles
Articles by the same authors
Discussion board
Biomacromolecules 6(4): 1998-2007
PMID: 16004438

Functionalizing Electrospun Fibers with Biologically Relevant Macromolecules

Department of Materials Science and Engineering, University of Delaware, Newark, Delaware 19716, and Delaware Biotechnology Institute, 15 Innovation Way, Newark, Delaware 19711
To whom correspondence should be addressed. Address: 201 Dupont Hall, University of Delaware, Newark, DE, 19716. Tel: 302-831-4476. Fax: 302-831-4545. E-mail: ude.ledu@tlobar
Copyright notice

Abstract

The development of functionalized polymers that can elicit specific biological responses is of great interest in the biomedical community, as well as the development of methods to fabricate these biologically functionalized polymers. For example, the generation of fibrous matrices with biological properties and fiber diameters commensurate with those of the natural extracellular matrix (ECM) may permit the development of novel materials for use in wound healing or tissue engineering. The goal of this work is, therefore, to create a biologically active functionalized electrospun matrix to permit immobilization and long-term delivery of growth factors. In this work, poly(ethylene glycol) functionalized with low molecular weight heparin (PEG-LMWH) was fabricated into fibers for possible use in drug delivery, tissue engineering, or wound repair applications. Electrospinning was chosen to process the LMWH into fiber form due to the small fiber diameters and high degree of porosity that can be obtained relatively quickly and using small amounts of starting material. Both free LMWH and PEG-LMWH were investigated for their ability to be incorporated into electrospun fibers. Each of the samples were mixed with a carrier polymer consisting of either a 10 wt % poly(ethylene oxide) (PEO) or 45 wt % poly(lactide-co-glycolide) (PLGA). Field emission scanning electron microscopy (FESEM), energy-dispersive X-ray analysis (EDX), UV–vis spectroscopy, and multiphoton microscopy were used to characterize the electrospun matrices. The incorporation of heparin into the electrospun PEO and PLGA fibers did not affect the surface morphology or fiber diameters. The fibers produced had diameters ranging from approximately 100 to 400 nm. Toluidine blue assays of heparin suggest that it can be incorporated into an electrospun matrix at concentrations ranging from 3.5 to 85 μg per milligram of electrospun fibers. Multiphoton microscopy confirmed that incorporation of PEG-LMWH into the matrix permits retention of the heparin for at least 14 days. Improvements in the binding of basic fibroblast growth factor to the electrospun fibers were also observed for fibers functionalized with PEG-LMWH over those functionalized with LMWH alone. The combination of these results suggests the utility for producing electrospun fibers that are appropriately functionalized for use in biomaterials applications.

Abstract

Footnotes

Supporting Information Available. Experimental details and results. This material is available free of charge via the Internet at http://pubs.acs.org.

Footnotes

References and Notes

References and Notes

References

  • 1. Boland ED, Wnek GE, Simpson DG, Pawlowski KJ, Bowlin GL. J Macromol Sci-Pure Appl Chem. 2001;38:1231–1243.[PubMed]
  • 2. Boland ED, Bowlin GL, Simpson DG, Wnek GE. Abstr Papers Am Chem Soc. 2001;222:31-PMSE.[PubMed]
  • 3. Kenawy ER, Bowlin GL, Mansfield K, Layman J, Simpson DG, Sanders EH, Wnek GE. J Controlled Release. 2002;81:57–64.[PubMed]
  • 4. Kenawy ER, Abdel-Fattah YR. Macromol Biosci. 2002;2:261–266.[PubMed]
  • 5. Li WJ, Laurencin CT, Caterson EJ, Tuan RS, Ko FK. J Biomed Mater Res. 2002;60:613–621.[PubMed]
  • 6. Luu YK, Kim K, Hsiao BS, Chu B, Hadjiargyrou M. J Controlled Release. 2003;89:341–353.[PubMed]
  • 7. Matthews JA, Wnek GE, Simpson DG, Bowlin GL. Biomacromolecules. 2002;3:232–238.[PubMed]
  • 8. Wnek GE, Carr ME, Simpson DG, Bowlin GL. Nano Lett. 2003;3:213–216.[PubMed]
  • 9. Xu CY, Inai R, Kotaki M, Ramakrishna S. Biomaterials. 2004;25:877–886.[PubMed]
  • 10. Yoshimoto H, Shin YM, Terai H, Vacanti JP. Biomaterials. 2003;24:2077–2082.[PubMed]
  • 11. Zong XH, Kim K, Fang DF, Ran SF, Hsiao BS, Chu B. Polymer. 2002;43:4403–4412.[PubMed]
  • 12. , 2005.[PubMed]
  • 13. , 2005.[PubMed]
  • 14. Jiang HL, Fang DF, Hsiao BJ, Chu BJ, Chen WL. J Biomater Sci-Polym Ed. 2004;15:279–296.[PubMed]
  • 15. Bhattarai SR, Bhattarai N, Yi HK, Hwang PH, Cha DI, Kim HY. Biomaterials. 2004;25:2595–2602.[PubMed]
  • 16. Sakiyama-Elbert SE, Hubbell JA. J Controlled Release. 2000;65:389–402.[PubMed]
  • 17. SchroederTefft JA, Bentz H, Estridge TD. J Controlled Release. 1997;48:29–33.[PubMed]
  • 18. Ishihara M, Obara K, Ishizuka T, Fujita M, Sato M, Masuoka K, Saito Y, Yura H, Matsui T, Hattori H, Kikuchi M, Kurita A. J Biomed Mater Res Part A. 2003;64A:551–559.[PubMed]
  • 19. Zisch AH, Lutolf MP, Hubbell JA. Cardiovasc Pathol. 2003;12:295–310.[PubMed]
  • 20. Griffith LG. Acta Mater. 2000;48:263–277.[PubMed]
  • 21. Irvine DJ, Mayes AM, Satija SK, Barker JG, Sofia-Allgor SJ, Griffith LG. J Biomed Mater Res. 1998;40:498–509.[PubMed]
  • 22. Li J, Ni XP, Leong KW. J Biomed Mater Res Part A. 2003;65A:196–202.[PubMed]
  • 23. Seal BL, Otero TC, Panitch A. Mater Sci Eng R-Rep. 2001;34:147–230.[PubMed]
  • 24. Hasirci V, Lewandrowski K, Gresser JD, Wise DL, Trantolo DJ. J Biotechnol. 2001;86:135–150.[PubMed]
  • 25. Karakecili AG, Gumusderelioglu M. J Biomater Sci-Polym Ed. 2002;13:185–196.[PubMed]
  • 26. Miller DC, Thapa A, Haberstroh KM, Webster TJ. Biomaterials. 2004;25:53–61.[PubMed]
  • 27. Ishihara M, Sato M, Hattori H, Saito Y, Yura H, Ono K, Masuoka K, Kikuchi M, Fujikawa K, Kurita A. J Biomed Mater Res. 2001;56:536–544.[PubMed]
  • 28. Guan R, Sun XL, Hou SJ, Wu PY, Chaikof EL. Bioconjugate Chem. 2004;15:145–151.[PubMed]
  • 29. Lieberman JR, Daluiski A, Einhorn TA. J Bone Joint Surg-Am Volume. 2002;84A:1032–1044.[PubMed]
  • 30. Sakiyama-Elbert SE, Hubbell JA. J Controlled Release. 2000;69:149–158.[PubMed]
  • 31. Seal BL, Panitch A. Biomacromolecules. 2003;4:1572–1582.[PubMed]
  • 32. Hennink WE, van Nostrum CF. Adv Drug Delivery Rev. 2002;54:13–36.[PubMed]
  • 33. Casper CL, Yamaguchi N, Chase DB, Rabolt JF, Kiick KL Functionalized electrospun fibers for potential use in biomedical applications. Vol. 91. Philadelphia, PA: 2004. p. 1030. [PubMed][Google Scholar]
  • 34. Yamaguchi N, Kiick KL. Biomacromolecules. 2005 accepted. [PubMed]
  • 35. Zhou D, Too CO, Wallace GG. React Funct Polym. 1999;39:19–26.[PubMed]
  • 36. Czymmek, KPrivate communication, 2004.
  • 37. Fong H, Chun I, Reneker DH. Polymer. 1999;40:4585–4592.[PubMed]
  • 38. Koski A, Yim K, Shivkumar S. Materials Lett. 2004;58:493–497.[PubMed]
  • 39. Son WK, Youk JH, Lee TS, Park WH. Polymer. 2004;45:2959–2966.[PubMed]
  • 40. Casper CL, Yang W, Farach-Carson MC, Rabolt JF ACS Symposium Series Book. 2004. submitted, Polymeric Nanofibers. [PubMed][Google Scholar]
  • 41. Reyderman L, Stavchansky S. Int J Pharm. 1995;124:75–85.[PubMed]
  • 42. Jing Z, Xu XY, Chen XS, Liang QZ, Bian XC, Yang LX, Jing XB. J Controlled Release. 2003;92:227–231.[PubMed]
  • 43. Huang L, McMillan RA, Apkarian RP, Pourdeyhimi B, Conticello VP, Chaikof EL. Macromolecules. 2000;33:2989–2997.[PubMed]
  • 44. Nagapudi K, Brinkman WT, Leisen JE, Huang L, McMillan RA, Apkarian RP, Conticello VP, Chaikof EL. Macromolecules. 2002;35:1730–1737.[PubMed]
  • 45. Roghani M, Mansukhani A, Dellera P, Bellosta P, Basilico C, Rifkin DB, Moscatelli D. J Biol Chem. 1994;269:3976–3984.[PubMed]
  • 46. Chintala SK, Miller RR, McDevitt CA. Arch Biochem Biophys. 1994;310:180–186.[PubMed]
  • 47. Mach H, Volkin DB, Burke CJ, Middaugh CR, Linhardt RJ, Fromm JR, Loganathan D, Mattsson L. Biochemistry. 1993;32:5480–5489.[PubMed]
  • 48. Vlodavsky I, Fuks Z, Ishaimichaeli R, Bashkin P, Levi E, Korner G, Barshavit R, Klagsbrun M. J Cellular Biochem. 1991;45:167–176.[PubMed]
Collaboration tool especially designed for Life Science professionals.Drag-and-drop any entity to your messages.